Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II clinical study of CTR-107 (Noregen™) for Retinal Diseases

Trial Profile

Phase I/II clinical study of CTR-107 (Noregen™) for Retinal Diseases

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTR 107 (Primary)
  • Indications Retinal disorders
  • Focus Adverse reactions

Most Recent Events

  • 05 Jul 2023 New trial record
  • 28 Jun 2023 According to an Wacker Biotech media release, Caeregen Therapeutics and Wacker Biotech will collaborate on the development and production of CTR-107 (Noregen™) for the treatment of retinal-related vision loss.
  • 28 Jun 2023 According to an Wacker Biotech media release, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands to support this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top